<?xml version='1.0' encoding='utf-8'?>
<document id="28503751"><sentence text="In vitro evaluation of potential transporter-mediated drug interactions of evogliptin."><entity charOffset="75-85" id="DDI-PubMed.28503751.s1.e0" text="evogliptin" /></sentence><sentence text="To date, little is known about the transporter-mediated drug-drug interaction (DDI) potential of evogliptin, a novel DPP-4 inhibitor"><entity charOffset="97-107" id="DDI-PubMed.28503751.s2.e0" text="evogliptin" /></sentence><sentence text=" The objective of this study was to evaluate the DDI potential of evogliptin using various in vitro assays in transporter-expressing cell lines"><entity charOffset="66-76" id="DDI-PubMed.28503751.s3.e0" text="evogliptin" /></sentence><sentence text=" After incubating evogliptin with cells overexpressing OAT1, OAT3, OCT2, OATP1B1 and OATP1B3, there was no notable cellular accumulation of evogliptin (fold accumulation, 0"><entity charOffset="18-28" id="DDI-PubMed.28503751.s4.e0" text="evogliptin" /><entity charOffset="140-150" id="DDI-PubMed.28503751.s4.e1" text="evogliptin" /><pair ddi="false" e1="DDI-PubMed.28503751.s4.e0" e2="DDI-PubMed.28503751.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28503751.s4.e0" e2="DDI-PubMed.28503751.s4.e1" /></sentence><sentence text="41-1" /><sentence text="86)" /><sentence text=" In bidirectional transport assays using a Caco-2 cell monolayer, a high efflux ratio (ER, 522) of evogliptin was observed, which was significantly decreased (97"><entity charOffset="99-109" id="DDI-PubMed.28503751.s7.e0" text="evogliptin" /></sentence><sentence text="96%) in the presence of a potent P-gp inhibitor" /><sentence text=" In assays using MDCKII-BCRP cell monolayers, by contrast, a low net ER (1" /><sentence text="16-1" /><sentence text="26) was found" /><sentence text=" In similar cellular uptake and bidirectional studies with probe substrates of P-gp, BCRP, OAT1, OAT3, OCT2, OATP1B1 and OATP1B3, the active transport of the substrates was not significantly suppressed by evogliptin"><entity charOffset="205-215" id="DDI-PubMed.28503751.s12.e0" text="evogliptin" /></sentence><sentence text=" These results suggest that evogliptin may be a substrate of P-gp, but not a substrate of BCRP, OAT1B1, OAT1B3, OAT1, OAT3 or OCT2, and not an inhibitor of any of these transporters"><entity charOffset="28-38" id="DDI-PubMed.28503751.s13.e0" text="evogliptin" /></sentence><sentence text=" Therefore, it could be concluded that evogliptin has some DDI potential involving P-gp, but it has low potential of DDI mediated by the other transporters"><entity charOffset="39-49" id="DDI-PubMed.28503751.s14.e0" text="evogliptin" /></sentence><sentence text="" /></document>